| Chronic graft-versus-host disease
Rezurock vs Jakafi
Side-by-side clinical, coverage, and cost comparison for chronic graft-versus-host disease.Deep comparison between: Rezurock vs Jakafi with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsJakafi has a higher rate of injection site reactions vs Rezurock based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Jakafi but not Rezurock, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Rezurock
Jakafi
At A Glance
Oral
Daily
ROCK2 inhibitor
Oral
Twice daily
JAK1/JAK2 inhibitor
Indications
- Chronic graft-versus-host disease
- Myelofibrosis
- Polycythemia Vera
- Acute GVH disease
- Chronic graft-versus-host disease
Dosing
Chronic graft-versus-host disease 200 mg orally once daily with food until progression of chronic GVHD requiring new systemic therapy; increase to 200 mg twice daily when coadministered with strong CYP3A inducers or proton pump inhibitors.
Myelofibrosis Starting dose based on platelet count: 20 mg orally twice daily (>200 x 10^9/L), 15 mg twice daily (100-200 x 10^9/L), or 5 mg twice daily (50 to <100 x 10^9/L); doses may be titrated up to 25 mg twice daily based on safety and efficacy.
Polycythemia Vera 10 mg orally twice daily starting dose; doses may be titrated up to 25 mg twice daily based on safety and efficacy.
Acute GVH disease 5 mg orally twice daily starting dose; may increase to 10 mg twice daily after at least 3 days if ANC and platelet counts are not decreased by 50% or more relative to the first day of dosing.
Chronic graft-versus-host disease 10 mg orally twice daily starting dose; taper after 6 months in patients with response who have discontinued therapeutic doses of corticosteroids.
Contraindications
—
—
Adverse Reactions
Most common (>=20%) Infections, asthenia, nausea, diarrhea, dyspnea, cough, edema, hemorrhage, abdominal pain, musculoskeletal pain, headache, phosphate decreased, gamma glutamyl transferase increased, lymphocytes decreased, hypertension
Most common Thrombocytopenia, anemia, neutropenia, bruising, dizziness, headache, infections, edema, hemorrhage, fatigue
Serious Thrombocytopenia, anemia, neutropenia, infections, non-melanoma skin cancer, major adverse cardiovascular events, thrombosis, secondary malignancies
Postmarketing Herpes simplex virus reactivation and/or dissemination
Pharmacology
Belumosudil is a ROCK inhibitor that selectively inhibits ROCK2 (IC50 approximately 100 nM) and ROCK1 (IC50 approximately 3 uM), down-regulating proinflammatory STAT3/STAT5 signaling and Th17/Treg imbalance while inhibiting pro-fibrotic signaling implicated in chronic GVHD.
Ruxolitinib is a kinase inhibitor that selectively inhibits JAK1 and JAK2, which mediate cytokine and growth factor signaling important for hematopoiesis and immune function; dysregulated JAK1/JAK2 signaling underlies myelofibrosis, polycythemia vera, and GVHD pathogenesis.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Rezurock
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (11/12) · Qty limit (9/12)
Jakafi
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (10/12) · Qty limit (11/12)
UnitedHealthcare
Rezurock
- Covered on 4 commercial plans
- PA (5/8) · Step Therapy (4/8) · Qty limit (1/8)
Jakafi
- Covered on 4 commercial plans
- PA (8/8) · Step Therapy (8/8) · Qty limit (7/8)
Humana
Rezurock
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (2/3) · Qty limit (3/3)
Jakafi
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (2/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
$10/momo
Kadmon ASSIST Copay Savings Card: RezurockCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
No savings programs available for Jakafi.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
RezurockView full Rezurock profile
JakafiView full Jakafi profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.